Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.33
TECH's Cash-to-Debt is ranked lower than
88% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. TECH: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
TECH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33  Med: No Debt Max: No Debt
Current: 0.33
Equity-to-Asset 0.59
TECH's Equity-to-Asset is ranked lower than
55% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. TECH: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
TECH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59  Med: 0.91 Max: 0.98
Current: 0.59
0.59
0.98
Interest Coverage 30.83
TECH's Interest Coverage is ranked lower than
79% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TECH: 30.83 )
Ranked among companies with meaningful Interest Coverage only.
TECH' s Interest Coverage Range Over the Past 10 Years
Min: 30.83  Med: No Debt Max: No Debt
Current: 30.83
Piotroski F-Score: 4
Altman Z-Score: 5.25
Beneish M-Score: -2.43
WACC vs ROIC
7.94%
8.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 23.69
TECH's Operating Margin % is ranked higher than
86% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. TECH: 23.69 )
Ranked among companies with meaningful Operating Margin % only.
TECH' s Operating Margin % Range Over the Past 10 Years
Min: 23.69  Med: 54.2 Max: 58.1
Current: 23.69
23.69
58.1
Net Margin % 14.87
TECH's Net Margin % is ranked higher than
83% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. TECH: 14.87 )
Ranked among companies with meaningful Net Margin % only.
TECH' s Net Margin % Range Over the Past 10 Years
Min: 14.87  Med: 37.16 Max: 40.8
Current: 14.87
14.87
40.8
ROE % 8.97
TECH's ROE % is ranked higher than
82% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. TECH: 8.97 )
Ranked among companies with meaningful ROE % only.
TECH' s ROE % Range Over the Past 10 Years
Min: 8.97  Med: 19.24 Max: 22.91
Current: 8.97
8.97
22.91
ROA % 6.11
TECH's ROA % is ranked higher than
84% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. TECH: 6.11 )
Ranked among companies with meaningful ROA % only.
TECH' s ROA % Range Over the Past 10 Years
Min: 6.11  Med: 18.28 Max: 22.16
Current: 6.11
6.11
22.16
ROC (Joel Greenblatt) % 53.41
TECH's ROC (Joel Greenblatt) % is ranked higher than
89% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. TECH: 53.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TECH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.41  Med: 110.2 Max: 120.19
Current: 53.41
53.41
120.19
3-Year Revenue Growth Rate 16.70
TECH's 3-Year Revenue Growth Rate is ranked higher than
69% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. TECH: 16.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TECH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 12.4 Max: 16.7
Current: 16.7
5.3
16.7
3-Year EBITDA Growth Rate 3.10
TECH's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. TECH: 3.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TECH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 1.8  Med: 11.6 Max: 41
Current: 3.1
1.8
41
3-Year EPS without NRI Growth Rate -2.80
TECH's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. TECH: -2.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TECH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -2.8  Med: 16.5 Max: 36.3
Current: -2.8
-2.8
36.3
GuruFocus has detected 6 Warning Signs with Bio-Techne Corp $TECH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TECH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TECH Guru Trades in Q1 2016

George Soros 18,000 sh (New)
Paul Tudor Jones 3,500 sh (New)
Ron Baron 1,658,440 sh (+10.79%)
Columbia Wanger 851,260 sh (+0.47%)
Mairs and Power 1,310,574 sh (+0.28%)
Ruane Cunniff Sold Out
Ray Dalio Sold Out
Chuck Royce 834,759 sh (-8.12%)
Jim Simons 104,100 sh (-34.86%)
» More
Q2 2016

TECH Guru Trades in Q2 2016

Paul Tudor Jones 7,700 sh (+120.00%)
Mairs and Power 1,351,264 sh (+3.10%)
George Soros Sold Out
Ron Baron 1,642,221 sh (-0.98%)
Chuck Royce 766,259 sh (-8.21%)
Columbia Wanger 726,445 sh (-14.66%)
Jim Simons 39,800 sh (-61.77%)
» More
Q3 2016

TECH Guru Trades in Q3 2016

Jim Simons 143,500 sh (+260.55%)
Mairs and Power 1,367,099 sh (+1.17%)
Paul Tudor Jones Sold Out
Ron Baron 1,636,421 sh (-0.35%)
Chuck Royce 741,359 sh (-3.25%)
Columbia Wanger 611,536 sh (-15.82%)
» More
Q4 2016

TECH Guru Trades in Q4 2016

Jim Simons 181,500 sh (+26.48%)
Chuck Royce 775,259 sh (+4.57%)
Mairs and Power 1,368,650 sh (+0.11%)
Ron Baron 1,600,092 sh (-2.22%)
Columbia Wanger 589,563 sh (-3.59%)
» More
» Details

Insider Trades

Latest Guru Trades with TECH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ALNY, NAS:BLUE, NAS:ARIA, NAS:ACAD, NAS:RARE, OTCPK:GLPGF, NAS:CBPO, NAS:ICPT, OTCPK:BTGGF, NAS:CLVS, NAS:IONS, NAS:SAGE, OTCPK:ABCZF, NAS:LGND, NAS:NKTR, NAS:AGIO, NAS:ONCE, NYSE:CBM, NAS:ARRY, NAS:SRPT » details
Traded in other countries:TE1.Germany,
Bio-Techne Corp and its subsidiaries develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. The Company's business segments are the Biotechnology, Clinical Controls and Protein Platforms divisions.

Bio-Techne Corp was founded as Research and Diagnostic Systems, Inc. (R&D Systems) in 1976. In November 2014, the company's name was changed from Techne Corporation to Bio-Techne Corporation. The Company and its subsidiaries develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. The Company's business segments are the Biotechnology, Clinical Controls and Protein Platforms divisions. The Biotechnology segment supply's the proteins, such as cytokines, growth factors, immunoassays, antibodies and related reagents, to the biotechnology research community. It isolates and produces proteins in a pure form either from the native cells or through recombinant DNA technology. The Clinical Controls segment develops and manufactures controls and calibrators for instruments in the global clinical market. The Company offers a wide range of hematology controls and calibrators for both impedance and laser type cell counters. It also supply's hematology control products for use as proficiency testing tools by laboratory certifying authorities in a number of states and countries. The Protein Platforms segment develops, manufactures and sells tools to make protein analysis simpler, more quantitative and reproduceable. The Company sells its protein platforms products directly to customers located in North America, western Europe and Japan. It also sells through third party distributors in China, southern Europe and the rest of the world. The Company's competitors include GE Healthcare Life Sciences, BD Biosciences, Merck KGaA/EMD Chemicals, Inc., PeproTech, Inc., Santa Cruz Biotechnology, Inc., Abcam plc., Thermo Fisher Scientific, Inc., Cayman Chemical Company and Enzo Biochem, Inc, Abbott Diagnostics, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Streck, Inc., Siemens Healthcare Diagnostics Inc. and Sysmex Corporation, Bio-Rad Laboratories, GE Healthcare, Merck KGaA, PerkinElmer and Thermo Fisher Scientific. It operates in United States, Europe, China, Other Asia and Rest of world. The Company is subject to the medical device excise tax which was included as part of the Affordable Care Act.

Guru Investment Theses on Bio-Techne Corp

Baron Funds Comments on Bio-Techne Corp - Nov 02, 2015

Bio-Techne Corporation (NASDAQ:TECH) sells specialized proteins, antibodies and other reagents, as well as instruments for protein analysis, to life sciences researchers at academic institutions, biopharmaceutical companies and government-funded research entities. Its products are used by scientists to investigate potential therapies for disease. Most of the company’s products are for research purposes only, and so they avoid the need for expensive, time-consuming regulatory approvals. The products are also relatively inexpensive, and they generally do not represent large cost items in most clients’ research budgets. With a portfolio of more than 275,000 products, Bio-Techne has by far the largest portfolio in its field, making the company a key supplier across its customer base.





We have also owned this stock in Baron Growth Fund for many years. We believe that Bio-Techne has attractive financial characteristics, including consistent revenue growth potential, high profit margins potential, and low capital requirements. We also believe the company has a reputation for manufacturing high quality, reliable, consistent products. The company has a staff of scientists who stay current with scientific advances and areas of interest for researchers and help direct product development into these growing areas.





Starting in 2010, the company’s organic growth slowed to the low single digits because of academic funding constraints, which hurt customer spending, and a lack of re-investments in the business by the former management team. Chuck Kummeth, who assumed the CEO position in April 2013, has been taking steps to reinvigorate growth, including hiring new executives and salespeople, making acquisitions, and expanding in China where the government is committed to investing in life sciences research.





We bought the stock in the quarter because we believe the fundamentals of this attractive business will continue to improve. In the most recently reported quarter, organic growth accelerated to 7%, the highest level in years. The funding environment for the company’s customer base is stable. Drug development budgets are improving. There have been proposed increases in the NIH budget, though uncertainty about the final budget remains. The company is annualizing the acquisition of a business called Protein Simple, which we believe has potential to drive revenue growth acceleration through the sale of its innovative instrument platform that automates the Western Blotting technique. Management has an aspirational plan to grow the company’s revenues to $1 billion in the next five years. Despite improving fundamentals, the stock price trades at what we believe is an attractive level.



From the Baron Asset Fund shareholder letter Q3 2015 by Andrew Peck.



Check out Ron Baron latest stock trades

Top Ranked Articles about Bio-Techne Corp

Ron Baron's Stocks With Highest Returns Stocks held by the guru with the largest returns since the last trades
Ron Baron (Trades, Portfolio) is the founder of Baron Capital Management. He is co-portfolio manager of Baron Asset Fund and remains portfolio manager of the Growth and Partners Funds. He manages a portfolio composed of 296 stocks with a total value of $18.898 billion. Read more...

Ratios

vs
industry
vs
history
PE Ratio 50.76
TECH's PE Ratio is ranked lower than
73% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. TECH: 50.76 )
Ranked among companies with meaningful PE Ratio only.
TECH' s PE Ratio Range Over the Past 10 Years
Min: 16.78  Med: 27.09 Max: 51.19
Current: 50.76
16.78
51.19
Forward PE Ratio 29.67
TECH's Forward PE Ratio is ranked lower than
71% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. TECH: 29.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 50.76
TECH's PE Ratio without NRI is ranked lower than
72% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 26.61 vs. TECH: 50.76 )
Ranked among companies with meaningful PE Ratio without NRI only.
TECH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 16.78  Med: 27.09 Max: 51.19
Current: 50.76
16.78
51.19
Price-to-Owner-Earnings 42.86
TECH's Price-to-Owner-Earnings is ranked lower than
66% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 25.00 vs. TECH: 42.86 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TECH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.03  Med: 26.38 Max: 43.22
Current: 42.86
17.03
43.22
PB Ratio 4.47
TECH's PB Ratio is ranked lower than
57% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. TECH: 4.47 )
Ranked among companies with meaningful PB Ratio only.
TECH' s PB Ratio Range Over the Past 10 Years
Min: 3.27  Med: 4.52 Max: 7.48
Current: 4.47
3.27
7.48
PS Ratio 7.55
TECH's PS Ratio is ranked higher than
55% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. TECH: 7.55 )
Ranked among companies with meaningful PS Ratio only.
TECH' s PS Ratio Range Over the Past 10 Years
Min: 6.63  Med: 8.92 Max: 12.52
Current: 7.55
6.63
12.52
Price-to-Free-Cash-Flow 30.66
TECH's Price-to-Free-Cash-Flow is ranked lower than
58% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 23.86 vs. TECH: 30.66 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TECH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 17.73  Med: 26.58 Max: 34.07
Current: 30.66
17.73
34.07
Price-to-Operating-Cash-Flow 28.23
TECH's Price-to-Operating-Cash-Flow is ranked lower than
61% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 22.05 vs. TECH: 28.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TECH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 15.79  Med: 23.66 Max: 31.6
Current: 28.23
15.79
31.6
EV-to-EBIT 34.50
TECH's EV-to-EBIT is ranked lower than
67% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. TECH: 34.50 )
Ranked among companies with meaningful EV-to-EBIT only.
TECH' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.8  Med: 17 Max: 34.9
Current: 34.5
9.8
34.9
EV-to-EBITDA 24.37
TECH's EV-to-EBITDA is ranked lower than
64% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. TECH: 24.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
TECH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 16 Max: 24.7
Current: 24.37
9.4
24.7
PEG Ratio 22.09
TECH's PEG Ratio is ranked lower than
96% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 1.81 vs. TECH: 22.09 )
Ranked among companies with meaningful PEG Ratio only.
TECH' s PEG Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.95 Max: 36.56
Current: 22.09
1.01
36.56
Shiller PE Ratio 35.65
TECH's Shiller PE Ratio is ranked higher than
65% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.81 vs. TECH: 35.65 )
Ranked among companies with meaningful Shiller PE Ratio only.
TECH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 24.48  Med: 33.3 Max: 56.47
Current: 35.65
24.48
56.47
Current Ratio 2.44
TECH's Current Ratio is ranked lower than
63% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. TECH: 2.44 )
Ranked among companies with meaningful Current Ratio only.
TECH' s Current Ratio Range Over the Past 10 Years
Min: 2.44  Med: 9.66 Max: 21.99
Current: 2.44
2.44
21.99
Quick Ratio 1.89
TECH's Quick Ratio is ranked lower than
66% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. TECH: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
TECH' s Quick Ratio Range Over the Past 10 Years
Min: 1.89  Med: 8.99 Max: 21.04
Current: 1.89
1.89
21.04
Days Inventory 126.28
TECH's Days Inventory is ranked higher than
51% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. TECH: 126.28 )
Ranked among companies with meaningful Days Inventory only.
TECH' s Days Inventory Range Over the Past 10 Years
Min: 63.05  Med: 115.62 Max: 192.76
Current: 126.28
63.05
192.76
Days Sales Outstanding 72.13
TECH's Days Sales Outstanding is ranked lower than
59% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. TECH: 72.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
TECH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.81  Med: 45.11 Max: 72.13
Current: 72.13
40.81
72.13
Days Payable 26.34
TECH's Days Payable is ranked lower than
75% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. TECH: 26.34 )
Ranked among companies with meaningful Days Payable only.
TECH' s Days Payable Range Over the Past 10 Years
Min: 26.34  Med: 33.49 Max: 54.23
Current: 26.34
26.34
54.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.20
TECH's Dividend Yield % is ranked lower than
55% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 1.45 vs. TECH: 1.20 )
Ranked among companies with meaningful Dividend Yield % only.
TECH' s Dividend Yield % Range Over the Past 10 Years
Min: 0.39  Med: 1.43 Max: 1.82
Current: 1.2
0.39
1.82
Dividend Payout Ratio 0.61
TECH's Dividend Payout Ratio is ranked lower than
63% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.35 vs. TECH: 0.61 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TECH' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.38 Max: 0.61
Current: 0.61
0.27
0.61
3-Year Dividend Growth Rate 2.70
TECH's 3-Year Dividend Growth Rate is ranked lower than
62% of the 82 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. TECH: 2.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TECH' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 14
Current: 2.7
0
14
Forward Dividend Yield % 1.20
TECH's Forward Dividend Yield % is ranked lower than
53% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. TECH: 1.20 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.47
TECH's 5-Year Yield-on-Cost % is ranked lower than
54% of the 291 Companies
in the Global Biotechnology industry.

( Industry Median: 1.59 vs. TECH: 1.47 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TECH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.47  Med: 1.73 Max: 2.2
Current: 1.47
0.47
2.2
3-Year Average Share Buyback Ratio -0.40
TECH's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. TECH: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TECH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 0.3 Max: 2.4
Current: -0.4
-3.1
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.86
TECH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 156 Companies
in the Global Biotechnology industry.

( Industry Median: 3.03 vs. TECH: 1.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TECH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.27  Med: 1.96 Max: 12.77
Current: 1.86
1.27
12.77
Price-to-Intrinsic-Value-DCF (Earnings Based) 4.74
TECH's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
95% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. TECH: 4.74 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.85
TECH's Price-to-Median-PS-Value is ranked higher than
62% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. TECH: 0.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TECH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.03 Max: 2.93
Current: 0.85
0.41
2.93
Earnings Yield (Greenblatt) % 2.90
TECH's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. TECH: 2.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TECH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.9  Med: 5.9 Max: 10.2
Current: 2.9
2.9
10.2
Forward Rate of Return (Yacktman) % 4.39
TECH's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.08 vs. TECH: 4.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TECH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.39  Med: 11.9 Max: 25.7
Current: 4.39
4.39
25.7

More Statistics

Revenue (TTM) (Mil) $528.1
EPS (TTM) $ 2.10
Beta0.76
Short Percentage of Float5.15%
52-Week Range $84.66 - 117.42
Shares Outstanding (Mil)37.31

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 564 607 656
EPS ($) 3.59 3.93 4.30
EPS without NRI ($) 3.59 3.93 4.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TECH

Headlines

Articles On GuruFocus.com
Ron Baron's Stocks With Highest Returns Jul 13 2016 
Mairs and Power Sells Baxalta, Walt Disney, Target Dec 16 2015 
Baron Funds Comments on Bio-Techne Corp Nov 02 2015 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Chuck Akre MA, AMT, ESGR, ROST, TECH, KMB; Sells WRB, CRI, GLRE, RP, XOM Feb 13 2011 
Techne Corp. Reports Operating Results (10-Q) Feb 09 2011 
Techne Corp. Reports Operating Results (10-Q) Nov 09 2010 
Techne Corp. Reports Operating Results (10-K) Aug 27 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Techne Corp. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
BIO-TECHNE CORP Financials Feb 15 2017
Implied Volatility Surging for Bio-Techne (TECH) Stock Options Feb 15 2017
Blog Coverage Inovio Inks Collaboration and License Deal with ApolloBio for Greater China Feb 14 2017
Bio-Techne To Present At The Leerink Partners 6th Annual Global Healthcare Conference Feb 13 2017
BIO-TECHNE CORP Files SEC form 10-Q, Quarterly Report Feb 09 2017
Bio-Techne Corp. :TECH-US: Earnings Analysis: Q2, 2017 By the Numbers : February 9, 2017 Feb 09 2017
Bio-Techne Named "Company of the Year" by Instrument Business Outlook Feb 09 2017
Coverage initiated on Bio-Techne by Citigroup Feb 09 2017
Edited Transcript of TECH earnings conference call or presentation 7-Feb-17 2:00pm GMT Feb 07 2017
BIO-TECHNE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Feb 07 2017
Bio-Techne Declares Dividend Feb 07 2017
Bio-Techne Releases Second Quarter Fiscal 2017 Results Feb 07 2017
Q2 2017 Bio-Techne Corp Earnings Release - Before Market Open Feb 07 2017
Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More Feb 06 2017
A Very Large Chunk of the Stock Market Has Gone Nowhere -- So Here Is What You Should Do Feb 03 2017
Bio-Techne To Host Conference Call On February 7, 2017 To Announce Second Quarter Financial Results Jan 25 2017
Bio-Techne Congratulates Astute Medical on Clinical Trial Results Jan 24 2017
COPD Biomarker Qualification Consortium Partners with Bio-Techne to Identify COPD Indicator Jan 11 2017
Bio-Techne Corp. breached its 50 day moving average in a Bullish Manner : TECH-US : January 5, 2017 Jan 05 2017
Bio-Techne Corp. breached its 50 day moving average in a Bearish Manner : TECH-US : December 15,... Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)